Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MAST2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MAST2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAST2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAST2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MAST2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0018105 | Colorectum | AD | peptidyl-serine phosphorylation | 88/3918 | 315/18723 | 1.73e-03 | 1.43e-02 | 88 |
GO:0018209 | Colorectum | AD | peptidyl-serine modification | 92/3918 | 338/18723 | 3.19e-03 | 2.36e-02 | 92 |
GO:00181051 | Colorectum | SER | peptidyl-serine phosphorylation | 66/2897 | 315/18723 | 5.47e-03 | 4.06e-02 | 66 |
GO:00181052 | Colorectum | MSS | peptidyl-serine phosphorylation | 81/3467 | 315/18723 | 8.92e-04 | 9.12e-03 | 81 |
GO:00182091 | Colorectum | MSS | peptidyl-serine modification | 84/3467 | 338/18723 | 2.12e-03 | 1.79e-02 | 84 |
GO:00181053 | Colorectum | FAP | peptidyl-serine phosphorylation | 71/2622 | 315/18723 | 2.51e-05 | 5.82e-04 | 71 |
GO:00182092 | Colorectum | FAP | peptidyl-serine modification | 73/2622 | 338/18723 | 8.47e-05 | 1.51e-03 | 73 |
GO:00181054 | Colorectum | CRC | peptidyl-serine phosphorylation | 61/2078 | 315/18723 | 9.88e-06 | 3.31e-04 | 61 |
GO:00182093 | Colorectum | CRC | peptidyl-serine modification | 62/2078 | 338/18723 | 4.67e-05 | 1.10e-03 | 62 |
GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
GO:00181055 | Liver | NAFLD | peptidyl-serine phosphorylation | 63/1882 | 315/18723 | 7.45e-08 | 6.60e-06 | 63 |
GO:00182094 | Liver | NAFLD | peptidyl-serine modification | 64/1882 | 338/18723 | 4.65e-07 | 2.89e-05 | 64 |
GO:001810511 | Liver | HCC | peptidyl-serine phosphorylation | 169/7958 | 315/18723 | 3.86e-05 | 3.81e-04 | 169 |
GO:001820911 | Liver | HCC | peptidyl-serine modification | 177/7958 | 338/18723 | 1.45e-04 | 1.17e-03 | 177 |
GO:00181056 | Lung | IAC | peptidyl-serine phosphorylation | 69/2061 | 315/18723 | 1.48e-08 | 1.87e-06 | 69 |
GO:00182095 | Lung | IAC | peptidyl-serine modification | 70/2061 | 338/18723 | 1.23e-07 | 1.10e-05 | 70 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAST2 | SNV | Missense_Mutation | | c.2749N>C | p.Glu917Gln | p.E917Q | Q6P0Q8 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.98) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAST2 | SNV | Missense_Mutation | | c.3928G>T | p.Gly1310Cys | p.G1310C | Q6P0Q8 | protein_coding | deleterious_low_confidence(0.01) | benign(0.006) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
MAST2 | SNV | Missense_Mutation | | c.2749N>A | p.Glu917Lys | p.E917K | Q6P0Q8 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.935) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAST2 | SNV | Missense_Mutation | | c.1620N>C | p.Met540Ile | p.M540I | Q6P0Q8 | protein_coding | tolerated_low_confidence(0.09) | possibly_damaging(0.627) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
MAST2 | SNV | Missense_Mutation | | c.1453N>G | p.Pro485Ala | p.P485A | Q6P0Q8 | protein_coding | tolerated_low_confidence(0.46) | benign(0.027) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAST2 | SNV | Missense_Mutation | | c.2245G>A | p.Glu749Lys | p.E749K | Q6P0Q8 | protein_coding | deleterious_low_confidence(0) | benign(0.297) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAST2 | SNV | Missense_Mutation | | c.2191N>C | p.Glu731Gln | p.E731Q | Q6P0Q8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.995) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
MAST2 | SNV | Missense_Mutation | novel | c.4268N>T | p.Ala1423Val | p.A1423V | Q6P0Q8 | protein_coding | tolerated_low_confidence(0.43) | benign(0) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAST2 | insertion | Frame_Shift_Ins | novel | c.1341_1342insCTCCTGGAATGCCTGGT | p.Ala448LeufsTer32 | p.A448Lfs*32 | Q6P0Q8 | protein_coding | | | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAST2 | insertion | Nonsense_Mutation | novel | c.3929_3930insTGAGACCAGAAGTTTGAGACCAGCCTAGCCAACATGGTGAAAC | p.Ser1311GlufsTer9 | p.S1311Efs*9 | Q6P0Q8 | protein_coding | | | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |